By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Ignyta 

11095 Flintkote Avenue
Suite D
San Diego  California  92121  U.S.A.
Phone: Fax:


SEARCH JOBS


Industry
Biotechnology






Company News
Ignyta (RXDX) Announces Multiple Presentations At The 2015 AACR Annual Meeting 4/20/2015 11:23:37 AM
Ignyta (RXDX) Announces 2014 Full Year Company Highlights And Financial Results 3/18/2015 10:07:09 AM
Ignyta (RXDX) Shells Out $41.6 Million for Teva (TEVA)'s Oncology Assets 3/18/2015 6:39:35 AM
Ignyta (RXDX) To Report 2014 Company Highlights And Financial Results And Host Conference Call And Webcast On March 17, 2015 3/11/2015 10:23:13 AM
Ignyta (RXDX) Receives Orphan Drug Designation From FDA For Entrectinib For The Treatment Of Molecularly Defined Subsets Of Colorectal Cancer 2/17/2015 11:08:23 AM
Ignyta (RXDX) To Present At 2015 Leerink Global Healthcare Conference 2/5/2015 11:14:39 AM
Ignyta (RXDX) Receives Orphan Drug Designation From FDA For Entrectinib For The Treatment Of Molecularly Defined Subsets Of Non-Small Cell Lung Cancer 2/5/2015 9:35:26 AM
Ignyta (RXDX) Expands Clinical Leadership Team With Appointments Of Pratik Multani, M.D., M.S., As Chief Medical Officer And Adrian Senderowicz, M.D., As Clinical And Regulatory Strategy Officer 2/2/2015 11:18:25 AM
Ignyta (RXDX) To Participate In Life Sciences Panel Discussions With Other Thought Leaders At The 2015 East/West CEO Conference 1/6/2015 11:39:04 AM
Ignyta (RXDX) Receives Orphan Drug Designation And Rare Pediatric Disease Designation From FDA For Entrectinib For The Treatment Of Neuroblastoma 12/29/2014 9:01:51 AM
123456
//-->